Document:

EX-10.8

 Exhibit 10.8 

AMENDMENT TO STOCK ISSUANCE AGREEMENT 

This AMENDMENT TO STOCK ISSUANCE AGREEMENT (the
“Amendment”) is effective as of November 8, 2017 (the “Amendment Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with
offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite
125, Tampa, FL 33634, U.S.A. (the “Company”). Intrexon on the one hand and the Company on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 

A. WHEREAS Intrexon and the Company are parties to that certain Exclusive Channel Collaboration Agreement,
effective June 5, 2012, as amended by that certain First Amendment to Exclusive Channel Collaboration Agreement, effective July 21, 2016 (the “ECC Agreement”), pursuant to which Intrexon appointed the Company as its
exclusive channel collaborator for developing and commercializing certain products in an exclusive field as defined by the ECC Agreement; 

B. WHEREAS Intrexon and the Company are also parties to that certain Stock Issuance Agreement, effective
June 5, 2012 (the “Stock Agreement”), pursuant to which Intrexon and the Company further defined certain rights and obligations of Intrexon and the Company in regards to equity of the Company potentially payable under
the ECC Agreement; 
 C. WHEREAS Intrexon and the Company, in conjunction with concurrent amendment of the ECC
Agreement effectuated under separate instrument of even date herewith (the “ECC Amendment”), now mutually desire to amend the Stock Agreement; 

D. NOW, THEREFORE, Intrexon and the Company agree to amend the terms of the Stock Agreement as
provided below, effective as of the Amendment Effective Date. 
  

	1.	GENERALLY 

 1.1 Capitalized terms present within this Amendment
that are not proper names or titles, that are not conventionally capitalized, or that are not otherwise defined within this Amendment shall have the meaning set forth in the Stock Agreement. 

 

	2.	AMENDMENTS TO THE AGREEMENT 

2.1 Milestones. Section 1.2 of the Stock Agreement is hereby replaced in its entirety with the following Section 1.2: 

 1.2 Milestones. Subject to the terms and conditions of this Agreement and the
Channel Agreement, upon the first instance of attainment of the commercialization milestones as set forth below, and with respect to only the first Oragenics Product (as defined in the Channel Agreement) developed under the Channel Agreement that
reaches any such milestone, the Company has agreed to make certain milestone payments (each a “Milestone Payment” and together “Milestone Payments”) as set forth in this Section 1.2. The Milestone Payments are
each payable in cash (subject to Section 5.2(b) of the Channel Agreement) by wire transfer to the account specified by Intrexon. The specific milestone payments due to Intrexon upon achievement of each of the Milestone Events are set forth in
Sections 1.2(a) through 1.2(c) below. 
 (a) The Company shall pay Intrexon a
one-time milestone payment in cash of twenty five million United States dollars ($25,000,000) (subject to Section 5.2(b) of the Channel Agreement) within six (6) months of the first instance of the
achievement of the Regulatory Approval Milestone Event. 
 (b) The Company shall pay Intrexon a one-time milestone payment in cash of five million United States dollars ($5,000,000) (subject to Section 5.2(b) of the Channel Agreement) within six (6) months of the first instance of the achievement of
the New Indication Milestone Event. 
 (c) The Company shall pay Intrexon a one-time
milestone payment in cash of five million United States dollars ($5,000,000) (subject to Section 5.2(b) of the Channel Agreement) within six (6) months of the first instance of the achievement of the New Product Milestone Event. 

(d) As used in this Section: 

(i) “FDA New Product Application” means a “New Drug Application” or a “Biologics License
Application” (as both of such are defined according to relevant FDA guidelines and regulations establishing the mechanisms for the submission of new drug products in the United States of America for regulatory approval prior to commercial sale
and marketing), but excluding any Supplemental FDA Applications. 
 (ii) “New Indication Milestone Event”
means for a given Oragenics Product, the approval of a Supplemental FDA Application with the FDA (or an equivalent filing with another equivalent regulatory agency) which Supplemental FDA Application sought approval of an indication for use of an
Oragenics Product other than the current regulatory-approved 

  
 2 

 
indication for the respective Oragenics Product. For the avoidance of doubt and clarification purposes, any occurrence of the New Indication Milestone Event shall not also be deemed the
occurrence of the New Product Milestone Event or vice versa. 
 (iii) “New Product Milestone Event” means
for a given Oragenics Product, the approval of a FDA New Product Application for such Oragenics Product that is deemed (according to relevant FDA guidelines) to be a different drug product than the first Oragenics Product that was clinically pursued
under the Lantibiotics Program (as defined in the Channel Agreement). For purposes of the New Product Milestone Event, the subject Oragenics Product shall be deemed to be a “different” Oragenics Product from the first Oragenics Product
(and thus constitute an occurrence of the New Product Milestone Event) if regulatory approval of the subject Oragenics Product had to be obtained from the FDA under a different FDA New Product Application than the first Oragenics Product. For the
avoidance of doubt and clarification purposes, any occurrence of the New Product Milestone Event shall not also be deemed the occurrence of the New Indication Milestone Event or vice versa. 

(iv) “Regulatory Approval Milestone Event” means for a given Oragenics Product, the approval of a FDA New
Product Application for such Oragenics Product by the FDA or equivalent regulatory action in a foreign jurisdiction. 
 (v)
“Supplemental FDA Application” means a “Supplemental New Drug Application” or a “Supplemental Biologics License Application” (as both of such are defined according to relevant FDA guidelines and regulations
establishing the mechanisms for the submission of data in support of the FDA granting approval for new, amended, and/or expanded label indications for a prior-approved drug product in the United States of America). 

The event giving rise to a milestone payment under subsections (a) through (c) of this Section 1.2 shall be a
“Milestone Event” and together, the “Milestone Events.” 
 2.2 Company Sale. Section 1.3 of the
Stock Agreement is hereby deleted in its entirety. 
 2.3 Capital Adjustments. Section 1.4 of the Stock Agreement is hereby
deleted in its entirety. 

  
 3 

 2.4 Closings. Section 2.2(b) of the Stock Agreement is hereby deleted in its entirety
and all references to a Subsequent Closing or Subsequent Closings are deleted in their entirety. 
  

	3.	MISCELLANEOUS 

 3.1 Full Force and Effect. This Amendment amends
the terms of the Stock Agreement and is deemed incorporated into the Stock Agreement. The provisions of the Stock Agreement as amended remain in full force and effect. 

3.2 Entire Agreement. This Amendment, together with the Stock Agreement, the ECC Amendment, and the ECC Agreement, constitutes the
entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or implied, are superseded hereby,
merged and canceled, and are null and void and of no effect. 
 3.3 Counterparts. This Amendment may be executed in one or more
counterparts, each of which will be an original and all of which together will constitute one instrument. 
 [Remainder of Page
Intentionally Left Blank; Signature Page Follows] 

  
 4 

 IN WITNESS WHEREOF, Intrexon
and the Company have executed this Amendment by their respective duly authorized representatives as of the Amendment Effective Date. 
  

									
	INTREXON CORPORATION	 		  	 ORAGENICS, INC.

					
	By:	 	 /s/ Donald P. Lehr
	 		  	By:	  	 /s/ Alan Joslyn

	 Name: Donald P. Lehr
 Title: Chief
Legal Officer
	 		  	 Name: Alan Joslyn
 Title: Chief
Executive Officer

 Signature Page to Amendment to Stock Issuance AgreementEX-10.11

 Exhibit 10.11 

SECOND AMENDMENT TO EXCLUSIVE CHANNEL
COLLABORATION AGREEMENT 
 This SECOND AMENDMENT TO
EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Amendment”) is effective as of November 8, 2017 (the “Amendment Effective Date”) by and
between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), INTREXON
ACTOBIOTICS NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no. 0882.251.820 (Ghent), Belgium (“Actobiotics”), and
ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (“Oragenics”). Intrexon and Actobiotics together on
the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 

A. WHEREAS Intrexon, Actobiotics, and Oragenics are parties to that certain Exclusive Channel Collaboration
Agreement, effective June 9, 2015, as amended by that certain Amendment to Exclusive Channel Collaboration Agreement, effective May 10, 2017 (the “Agreement”), pursuant to which Intrexon and Actobiotics collectively
appointed Oragenics as their exclusive channel collaborator for developing and commercializing certain products in an exclusive field as defined by the Agreement; 

B. WHEREAS Intrexon, Actobiotics, and Oragenics all now mutually desire to amend the Agreement; 

D. NOW, THEREFORE, Intrexon, Actobiotics, and Oragenics agree to amend the terms of the Agreement
as provided below, effective as of the Amendment Effective Date. 
  

	1.	GENERALLY 

 1.1 Capitalized terms present within this Amendment
that are not proper names or titles, that are not conventionally capitalized, or that are not otherwise defined within this Amendment shall have the meaning set forth in the Agreement. 

1.2 Intrexon and Oragenics, in conjunction with and contemporaneously with this Amendment, have entered into an Amendment to Stock
Issuance Agreement of even date herewith (the “Stock Amendment”), which Stock Amendment amends the stock Issuance Agreement by and between Intrexon and Oragenics, effective June 9, 2015, as amended by that certain Amendment to
Stock Issuance Agreement, effective May 10, 2017 (the “Stock Agreement”). 
  

	2.	AMENDMENTS TO THE AGREEMENT 

2.1 Definitions. 

 (a) Section 1.6 of the Agreement “Approval Milestone Event”,
Section 1.58 of the Agreement “Phase II Milestone Event”, Section 1.59 of the Agreement “Phase IIb/III Milestone Event”, and Section 1.60 of the Agreement “Prior Field” are hereby
deleted in their entirety and each replaced with “Reserved”. 
 (b) Section 1.14 of the Agreement is hereby replaced in
its entirety with the following new Section 1.14: 
 “Commercialization Milestone Event” means any one of the
Regulatory Approval Milestone Event, the New Indication Milestone Event, and the New Product Milestone Event. 
 (c) Section 1.27
of the Agreement is hereby replaced in its entirety with the following new Section 1.27: 
 “Field” means,
irrespective of whether such requires regulatory approval, the treatment of oral mucositis in humans through the administration of an effector via genetically modified bacteria. Notwithstanding the foregoing, the Field shall exclude the
delivery of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer. 
 (d) Section 1.50 of the Agreement is
hereby replaced in its entirety with the following new Section 1.50: 
 “New Indication Milestone Event” means for a
given Oragenics Product, the approval of a Supplemental FDA Application with the FDA (or an equivalent filing with another equivalent regulatory agency) which Supplemental FDA Application sought approval of an indication for use of an Oragenics
Product other than the current regulatory-approved indication for the respective Oragenics Product. Notwithstanding the foregoing and in order to incentivize Oragenics to pursue new indications for the product AG013 in parallel with the existing
indication (as such existing indication is described in Investigational Drug Application no. 13995) for product AG013, the New Indication Milestone Event will be deemed not to have occurred if the filed regulatory package under the prior
sentence relies upon one or more human clinical trials for the specific new indication, which clinical trial(s) were conducted simultaneously and in parallel with human clinical trials underpinning the first-approved indication for AG013. For the
avoidance of doubt and clarification purposes, any occurrence of the New Indication Milestone Event shall not also be deemed the occurrence of the New Product Milestone Event or vice versa. 

  
 2 

 (e) Section 1.51 of the Agreement is hereby replaced in its entirety with the
following new Section 1.51: 
 “New Product Milestone Event” means for a given Oragenics Product, the approval of a
FDA New Product Application for such Oragenics Product that is deemed (according to relevant FDA guidelines) to be a different drug product than the first Oragenics Product that was clinically pursued under the Program. For purposes of the New
Product Milestone Event, the subject Oragenics Product shall be deemed to be a “different” Oragenics Product from the first Oragenics Product (and thus constitute an occurrence of the New Product Milestone Event) if regulatory approval of
the subject Oragenics Product had to be obtained from the FDA under a different FDA New Product Application than the first Oragenics Product. For the avoidance of doubt and clarification purposes, any occurrence of the New Product Milestone Event
shall not also be deemed the occurrence of the New Indication Milestone Event or vice versa. 
 (f) Section 1.68 of the Agreement
is hereby replaced in its entirety with the following new Section 1.68: 
 “Regulatory Approval Milestone Event” means
for a given Oragenics Product, the approval of a FDA New Product Application for such Oragenics Product by the FDA or equivalent regulatory action in a foreign jurisdiction. 

(g) Section 1.74(a) of the Agreement “Sublicensing Revenue Rate” is hereby amended by deleting “Sublicensing
Revenue Rate shall be fifty percent (50%)” and replacing it with “Sublicensing Revenue Rate shall be twenty five percent (25%)”. 

2.2 Milestones. Section 5.2(a) of the Agreement is hereby replaced in its entirety with the following new Section 5.2(a) and
all references in the Agreement to Sections 5.2(a)(i) through 5.2(a)(vi) shall refer to Sections 5.2(a)(i) through 5.2(a)(iii): 
 (a)
Oragenics Commercialization Milestones. Upon the first instance of attainment of certain Commercialization Milestone Events by an Oragenics Product (whether such attainment is achieved by Oragenics or by a permitted sublicensee), Oragenics has
agreed to pay Intrexon milestone payments as set forth in this Section 5.2. The milestone payments are each payable, at Oragenics’ election but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’
common stock (using Fair Market Value, as defined in the Equity Agreement, to calculate the number of shares to be issued to Intrexon in lieu of cash). The specific milestone payments due to Intrexon upon achievement of each of the Commercialization
Milestone Events are set forth in Sections 5.2(a)(i) through 5.3(a)(iii) below. 

  
 3 

 (i) Oragenics shall pay Intrexon a milestone payment of twenty seven million
five hundred thousand United States dollars ($27,500,000) within six (6) months of the first instance of the achievement of the Regulatory Approval Milestone Event, said payment being made, at Oragenics’ option but subject to Sections
5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock. 
 (ii) Oragenics shall pay Intrexon a one-time milestone payment of five million United States dollars ($5,000,000) within six (6) months of the first instance of the achievement of the New Indication Milestone Event, said payment being made, at
Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or in shares of Oragenics’ common stock. 

(iii) Oragenics shall pay Intrexon a one-time milestone payment of five million United
States dollars ($5,000,000) within six (6) months of the first instance of the achievement of the New Product Milestone Event, said payment being made, at Oragenics’ option but subject to Sections 5.2(b) through 5.2(d), either in cash or
in shares of Oragenics’ common stock. 
 Notwithstanding anything in this Agreement to the contrary, but subject to its
obligation under Section 4.5(a), Oragenics shall have sole and exclusive control over clinical trials (including patient dosing) and regulatory filings (including the jurisdictions in which such filings are made) for the purpose of the
Commercialization Milestones in Section 5.2(a)(i)-(iii) as applicable. 
  

	3.	MISCELLANEOUS 

 3.1 Full Force and Effect. This Amendment amends
the terms of the Agreement and is deemed incorporated into the Agreement. The provisions of the Agreement as amended remain in full force and effect. 

3.2 Entire Agreement. This Amendment, together with the Agreement, the Stock Agreement, and the Stock Amendment, constitutes the entire
agreement, both written and oral, between the Parties with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or implied, are superseded hereby, merged
and canceled, and are null and void and of no effect. 
 3.3 Counterparts. This Amendment may be executed in one or more counterparts,
each of which will be an original and all of which together will constitute one instrument. 

  
 4 

 IN WITNESS WHEREOF, Intrexon,
Actobiotics, and Oragenics have executed this Amendment by their respective duly authorized representatives as of the Amendment Effective Date. 
  

			
	INTREXON CORPORATION	  	 ORAGENICS, INC.

		
	 By: /s/ Donald P.
Lehr                                         
       
 Name: Donald P. Lehr

Title: Chief Legal Officer
	  	 By: /s/ Alan
Joslyn                                        
            
 Name: Alan Joslyn

Title: Chief Executive Officer

  

	
	INTREXON ACTOBIOTICS NV
	
	 By: /s/ Ricky
Sterling                                        
        
 Name: Ricky Sterling

Title: Director

 Signature Page to Second Amendment to Exclusive Channel Collaboration Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]